The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension remains a significant global health concern.
• Hydrochlorothiazide (HCTZ) is a commonly used diuretic for hypertension management.
• Some patients require combination therapy for adequate blood pressure control.

Purpose of the Study:

• To evaluate the short-term safety and efficacy of carvedilol added to hydrochlorothiazide (HCTZ) in patients with inadequately controlled hypertension.
• To assess the impact of combination therapy on blood pressure and heart rate.

Main Methods:

• A single-blind, single-center study involving 16 patients with supine diastolic blood pressure (DBP) ≥ 95 mm Hg.
• Patients received HCTZ 25 mg daily, then combination therapy with HCTZ 25 mg plus carvedilol (titrated from 12.5 mg to 25 mg daily).
• Blood pressure and heart rate were monitored at baseline and during combination treatment.

Main Results:

• Combination therapy significantly reduced mean trough blood pressure compared to baseline.
• After 2 days of 12.5 mg carvedilol, 38% of patients achieved DBP < 90 mm Hg.
• After 1 week of 25 mg carvedilol, 53% achieved DBP < 90 mm Hg and 93% achieved DBP < 95 mm Hg.
• Blood pressure reduction was most pronounced within 2 hours post-dosing.
• Heart rate remained minimally affected.

Conclusions:

• Combination therapy with carvedilol and HCTZ is effective for short-term blood pressure reduction in patients with inadequately controlled hypertension.
• The combination therapy was generally well-tolerated, with adverse events reported in 9 patients.
• Carvedilol addition to HCTZ offers a viable option for enhancing antihypertensive treatment.